Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center

Autor: Sofi Isaksson, MD, PhD, Bassam Hazem, MD, Mats Jönsson, PhD, Christel Reuterswärd, MSc, Anna Karlsson, PhD, Håkan Griph, MD, Jens Engleson, MD, Gudrun Oskarsdottir, MD, PhD, Ronny Öhman, MD, PhD, Karolina Holm, PhD, Frida Rosengren, MSc, Karin Annersten, BSc, Göran Jönsson, PhD, Åke Borg, PhD, Anders Edsjö, MD, PhD, Per Levéen, PhD, Hans Brunnström, MD, PhD, Kajsa Ericson Lindquist, MD, PhD, Johan Staaf, PhD, Maria Planck, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 1, Iss 1, Pp 100013- (2020)

Objectives: Mutation analysis by massive parallel sequencing (MPS) is routinely performed in the clinical management of lung cancer in Sweden. We describe the clinical and mutational profiles of lung cancer patients subjected to the first 1.5 years o

Externí odkaz: https://doaj.org/article/53ddcb953dc24827baf6b71f1fbffe14

Targeted sequencing may facilitate differential diagnostics of pulmonary tumours: a case series

Autor: Kajsa Ericson-Lindquist, Anna Johansson, Per Levéen, Göran Elmberger, Göran Jönsson, Johan Staaf, Hans Brunnström

Publikováno v: Diagnostic Pathology, Vol 12, Iss 1, Pp 1-14 (2017)

Abstract Background Histopathological diagnosis is important for prognostication and choice of treatment in patients with cancer in the lung. Metastases to the lungs are common and need to be distinguished from primary lung cancer. Furthermore, cases

Externí odkaz: https://doaj.org/article/2e7d2794f8b8450ca04523cbbc8f2885

PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature

Autor: Maria Planck, Lena Tran, Despoina Violidaki, Mohammed S. I. Mansour, Tomas Seidal, Benjamin Holmgren, Annika Dejmek, Kim Hejny, Katalin Dobra, Kajsa Ericson Lindquist, Rikard Mohlin, Hans Brunnström, Ulrich Mager

Publikováno v: Acta Cytol

Introduction: Programmed death-ligand 1 (PD-L1) expression is used for treatment prediction in non-small cell lung cancer (NSCLC). While cytology may be the only available material in the routine clinical setting, testing in clinical trials has mainl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b730b752be77e0e94f5157abf0cc3c6
https://doi.org/10.1159/000517078

PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations

Autor: Mohammed S I, Mansour, Karina, Malmros, Ulrich, Mager, Kajsa, Ericson Lindquist, Kim, Hejny, Benjamin, Holmgren, Tomas, Seidal, Annika, Dejmek, Katalin, Dobra, Maria, Planck, Hans, Brunnström

Publikováno v: International journal of molecular sciences. 23(9)

Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 or its ligand (PD-L1) have improved outcomes in non-small cell lung cancer (NSCLC). High tumor PD-L1 expression, detected by immunohistochemistry (IHC) typically on formalin-fixed p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fd7848056da6fac306e38a60f7923df6
https://pubmed.ncbi.nlm.nih.gov/35562908

Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe

Autor: Miguel Angel Molina Vila, Fernando Schmitt, Matteo Fassan, Umberto Malapelle, Elisa Gruppioni, Kajsa Ericson Lindquist, Oliver Schildgen, Antonino Iaccarino, Massimo Barberis, Svenja Wagener-Ryczek, Elena Vigliar, Luisella Righi, Marco Volante, Ida Rapa, Hans Brunnström, Giovanni Tallini, Sabine Merkelbach-Bruse, Dario de Biase, Giancarlo Troncone, Rafael Rosell, Birgit Weynand, Giovanna De Maglio, Verena Schildgen, Claudio Bellevicine, Pasquale Pisapia, Sara Vander Borght, Paul Hofman, Gabriella Fontanini, Anaïs Pujals

Publikováno v: Journal of Clinical Pathology
Journal Of Clinical Pathology
r-IGTP: Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Universidad de Alicante (UA)

AimsLung cancer predictive biomarker testing is essential to select advanced-stage patients for targeted treatments and should be carried out without delays even during health emergencies, such as the coronavirus (COVID-19) outbreak.MethodsFifteen mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f37400b73f8c4b71de7201e4369a434
http://hdl.handle.net/11588/828176